文献速递骨软组织肉瘤与黑色素瘤

达拉非尼联合曲美替尼治疗后缓解、疾病进展与总生存的预测因素:随机试验个体患者数据的汇总分析

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
PubMed 文献 · Lancet Oncol · 2016-11-16

本研究汇总BRF113220、COMBI-d、COMBI-v三项随机试验中617例BRAFV600E或BRAFV600K突变转移性黑色素瘤初治患者的个体数据,分析基线与治疗中因素同无进展生存和总生存的关联。中位随访20.0个月,中位无进展生存11.1个月、中位总生存25.6个月;乳酸脱氢酶正常且转移器官少于3个者预后最好,乳酸脱氢酶≥2倍正常上限者最差。

要点

  • 乳酸脱氢酶正常且转移器官少于3个者1年无进展生存68%、总生存90%。
  • 乳酸脱氢酶≥2倍正常上限者1年无进展生存8%、总生存40%。
  • 进展后生存以基线或新发非中枢神经系统病灶进展者最长,中位10.0个月。

核心结论

  • 多项基线与基线后患者及临床特征与达拉非尼联合曲美替尼的结局相关,在特定患者亚组中靶向治疗可能获得持久获益。

研究设计与样本

  • 基于已发表的随机试验进行回顾性个体数据分析,纳入接受达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次获批剂量的BRAFV600E或BRAFV600K突变转移性黑色素瘤初治患者。
  • 数据汇总自BRF113220(C部分;2010年3月26日至2015年1月15日)、COMBI-d(2012年5月4日至2015年1月12日)和COMBI-v(2012年6月4日至2015年3月13日)三项随机试验。
  • 这些试验不允许有未经治疗脑转移的患者入组;共纳入617例患者,中位随访20.0个月(范围0-48.0,四分位间距10.1-24.8)。
  • 采用单因素和多因素分析评估基线因素与无进展生存和总生存的关联,并用回归树分析评估其对结局的层级效应;另分析基线后、治疗中及进展时因素与进展后生存的关联。

主要发现

  • 617例患者中396例发生进展事件(疾病进展或死亡),290例死亡。
  • 中位无进展生存11.1个月(95% CI 9.7-12.9),中位总生存25.6个月(95% CI 23.1-34.3)。
  • 1年无进展生存48%(95% CI 44-52)、总生存74%(95% CI 71-78);2年无进展生存30%(95% CI 26-34)、总生存53%(95% CI 49-57)。
  • 乳酸脱氢酶浓度正常且转移器官少于3个者(n=237)1年无进展生存68%(95% CI 62-74)、总生存90%(95% CI 87-94),2年无进展生存46%(95% CI 40-54)、总生存75%(95% CI 70-81)。
  • 乳酸脱氢酶浓度至少为正常上限2倍者(n=70)1年无进展生存8%(95% CI 3-19)、总生存40%(95% CI 29-55),2年无进展生存2%(95% CI 0-13)、总生存7%(95% CI 3-19)。

关键数值与推荐

  • 乳酸脱氢酶正常且转移器官少于3个(n=237):1年无进展生存68%、总生存90%,2年无进展生存46%、总生存75%。
  • 乳酸脱氢酶至少为正常上限2倍(n=70):1年无进展生存8%、总生存40%,2年无进展生存2%、总生存7%。
  • 进展后中位生存:基线或新发非中枢神经系统病灶进展者10.0个月,新发中枢神经系统病灶或基线与新发病灶同时进展者4.0个月。

临床怎么用

  • 作者认为,基线和基线后的多项患者及临床特征与达拉非尼联合曲美替尼的结局相关,在特定患者亚组中靶向治疗可能获得持久获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dabrafenib plus trametinib treatment provides significant benefits over BRAF-inhibitor monotherapy in patients with BRAFV600E-mutant or BRAFV600K-mutant advanced melanoma; however, in many patients the disease progresses, leading to death. With many treatment options available, understanding clinical factors that predict long-term response and survival for treatments is important for optimisation of patient management. We aimed to identify clinical factors associated with long-term response and survival using pooled data from randomised trials of dabrafenib plus trametinib in patients with metastatic BRAF-mutant melanoma. METHODS: We did a retrospective individual data analysis based on all published randomised trials that included treatment-naive patients with BRAFV600E-mutant or BRAFV600K-mutant metastatic melanoma who received the approved dose of dabrafenib 150 mg twice daily plus trametinib 2 mg once daily. Data were pooled from patients in the BRF113220 (part C; March 26, 2010, to Jan 15, 2015), COMBI-d (May 4, 2012, to Jan 12, 2015), and COMBI-v (June 4, 2012, to March 13, 2015) randomised trials. Patients with untreated brain metastases were not permitted to enrol in these trials. Baseline factors, identified a priori based on known melanoma clinical or prognostic characteristics, were analysed for association with progression-free survival and overall survival using univariate and multivariate analyses and assessed for hierarchical effect on outcomes using regression tree analyses. We also analysed factors identified after baseline, on treatment, and at progression, for associations with survival after progression. The trials included in this analysis are registered with ClinicalTrials.gov: BRF113220, number NCT01072175; COMBI-d, number NCT01584648; COMBI-v, number NCT01597908. FINDINGS: 617 patients were included in this analysis with a median follow-up of 20·0 months (range 0-48·0, IQR 10·1-24·8); 396 patients had progression events (ie, disease progression or death) and 290 patients had died. Median progression-free survival (11·1 months [95% CI 9·7-12·9]), median overall survival (25·6 months [23·1-34·3]), 1-year progression-free survival (48% [44-52]) and overall survival (74% [71-78]), and 2-year progression-free survival (30% [26-34]) and overall survival (53% [49-57]) were consistent with those in the individual trials. Patients with normal lactate dehydrogenase (LDH) concentration and fewer than three organ sites containing metastases (n=237) had the longest 1-year progression-free survival (68% [95% CI 62-74]) and overall survival (90% [87-94]) and 2-year progression-free survival (46% [40-54]) and overall survival (75% [70-81]), whereas patients with LDH concentration at least two times the upper limit of normal (n=70) had the shortest 1-year progression-free survival (8% [3-19]) and overall survival (40% [29-55]) and 2-year progression-free survival (2% [0-13]) and overall survival (7% [3-19]). Of patients with disease progression (n=379), survival after progression was longest in those with progression in baseline or new non-CNS lesions (n=205; median 10·0 months [95% CI 7·9-12·0]) and shortest in those with new CNS lesions or concurrent progression in baseline and new lesions (n=171; median 4·0 months [3·5-4·9]). INTERPRETATION: Several patient and clinical characteristics at and after baseline are associated with outcomes with dabrafenib plus trametinib, and durable benefit is possible with targeted treatment in defined patient subsets. FUNDING: Novartis.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Long GV, Grob JJ, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016. PMID: 27864013. doi:10.1016/S1470-2045(16)30578-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。